AD

GRANT NUMBER DAMD17-98-1-8313

TITLE: Structural and Signaling Requirements for C-erbB2 Antiapoptosis in Breast Cancer

PRINCIPAL INVESTIGATOR: Tong Jing, B.M.

CONTRACTING ORGANIZATION: The University of Texas
M.D. Anderson Cancer Center
Houston, Texas 77030

REPORT DATE: June 1999

TYPE OF REPORT: Annual Summary

PREPARED FOR:
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
1. AGENCY USE ONLY (Leave blank)  

2. REPORT DATE  
June 1999

3. REPORT TYPE AND DATES COVERED  
Annual Summary (1 Jun 98 - 31 May 99)

4. TITLE AND SUBTITLE  
Structural and Signaling Requirements for C-erbB2 Antiapoptosis in Breast Cancer

5. FUNDING NUMBERS  
DAMD17-98-1-8313

6. AUTHOR(S)  
Tong Jing, B.M.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  
The University of Texas  
M.D. Anderson Cancer Center  
Houston, Texas 77030

E-Mail: tjing@mail.mdanderson.org

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT  
Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 words)  
The c-erbB2 (or HER-2, neu) gene encodes a 185-kDa transmembrane glycoprotein (p185), which is a growth factor receptor of the epidermal growth factor receptor (EGF-r) family. Our previous studies demonstrated that c-erbB2 overexpression can enhance metastatic potential and confer increased chemoresistance to breast cancer cells, thereby leading to poor clinical outcome in breast cancer patients. Our recent studies demonstrated that overexpression of the c-erbB2 gene can protect human breast cancer cells from apoptosis induced by the chemotherapeutic agent Taxol, by γ-radiation, or by serum starvation. These new findings provided an explanation on c-erbB2-mediated chemoresistance of breast cancer cells and poor prognosis of the patients. Therefore, it is very important to understand the mechanisms of antiapoptosis by c-erbB2. However, little is known about the molecular mechanisms of antiapoptosis by c-erbB2 overexpression in breast cancer cells. Since the p185c-erbB2 is a receptor tyrosine kinase (RTK), we hypothesize that c-erbB2 overexpression may enhance the RTK signaling capacity that activates downstream effectors for antiapoptotic signaling. In this application, I will study: (1) Identify structural requirements for c-erbB2 receptor antiapoptosis signaling. (2) Investigate the involvement of c-erbB2 immediate-downstream signaling (Shc-Grb2-Ras or PI3K) in antiapoptosis

14. SUBJECT TERMS  
Breast Cancer  
HER-2, apoptosis, tyrosine kinase

15. NUMBER OF PAGES  
19

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT  
Unclassified

18. SECURITY CLASSIFICATION OF THIS PAGE  
Unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT  
Unclassified

20. LIMITATION OF ABSTRACT  
Unlimited

NSN 7540-01-280-5500  
Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18 298-102  
USAPPC V1.00
FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

____ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

[Signature]

PI - Signature  5/25/99  Date
Table of Contents

2. Appendices
Progression Report for 1998-1999

A. Introduction

The c-erbB2 (or HER-2, neu) gene encodes a 185-kDa transmembrane glycoprotein (p185), which is a growth factor receptor of the epidermal growth factor receptor (EGF-r) family. Our previous studies demonstrated that c-erbB2 overexpression can enhance metastatic potential and confer increased chemoresistance to breast cancer cells, thereby leading to poor clinical outcome in breast cancer patients. Our recent studies demonstrated that overexpression of the c-erbB2 gene can protect human breast cancer cells from apoptosis induced by the chemotherapeutic agent Taxol, by γ-radiation, or by serum starvation. These new findings provided an explanation on c-erbB2-mediated chemoresistance of breast cancer cells and poor prognosis of the patients. Therefore, it is very important to understand the mechanisms of antiapoptosis by c-erbB2. However, little is known about the molecular mechanisms of antiapoptosis by c-erbB2 overexpression in breast cancer cells. Since the p185c-erbB2 is a receptor tyrosine kinase (RTK), we hypothesize that c-erbB2 overexpression may enhance the RTK signaling capacity that activates downstream effectors for antiapoptotic signaling. In this application, I will study: (1) Identify structural requirements for c-erbB2 receptor antiapoptosis signaling. (2) Investigate the involvement of c-erbB2 immediate-downstream signaling (Shc-Grb2-Ras or PI3K) in antiapoptosis.

B. Specific Aims

The specific Aims 1 and 2 have not been modified.

C. Study Results and Significance

Aim 1. Identify structural requirements for c-erbB2 receptor antiapoptosis signaling.

To determine whether the antiapoptotic signal of p185c-erbB2 require the tyrosine kinase activity and other structural motifs in the cytoplasmic domain, we have subcloned the K753M, Y1248F, Δ1050, Δ1076, and V659E series of mutants to the pcDNA3 vector and transfected these mutants into the p185-low-expressing MDA-MB-435 cells. Immunoblot analysis results show that these mutant erbB2 gene transfected cell lines expressed very high mutated erbB2 proteins at different
expression levels (Appendices Fig.1). To determine the structural changes in erbB2 mutants will result in specific changes in tyrosine phosphorylated proteins that correlate with their effects on antiapoptosis potential in MDA-MB-435 breast cancer cells, the tyrosine phosphorylation pattern of erbB2 proteins have been examined in vivo. As described in Appendices Fig. 2, western blotting using anti-phosphorylation antibodies was performed on protein lysates from MDA-MB-435 transfectants that express wild-type or mutant erbB2 proteins. As we expected, very low level of tyrosine phosphorylation of erbB2 protein has been found in transfectants that expressing the kinase-defective K753M mutant. This result indicate that K753M mutant protein is kinase defective in MDA-MB-435 cells. We also detected a reduction in tyrosine phosphorylation of erbB2 proteins in MDA-MB-435 transfectants expressing either the Y1248F, C1025 mutant proteins compared to those expressing the wild-type erbB2 protein, which indicate lower intrinsic tyrosine kinase activities of Y1248F, C1025. Furthermore, we detected a higher tyrosine phosphorylation of erbB2 proteins in MDA-MB-435 transfectants expressing the constitutive activated V659E mutant proteins compared to those expressing the wild type erbB2 protein, which indicate higher intrinsic tyrosine kinase activities of this mutant. Currently, I am examining these mutants for their ability to protect breast cancer cells from Taxol-induced apoptosis using different assays.

D. Plans

Aim 1. Identify structural requirements for c-erbB2 receptor antiapoptosis signaling.
Establish stable c-erbB2 mutant-expressing transfectants and test their antiapoptosis function. Determine if defective tyrosine kinase of the c-erbB2 mutants may correspond to impaired antiapoptosis. Please refer to the original proposal for the detail.

Aim 2. Investigate the involvement of c-erbB2 immediate-downstream signaling in antiapoptosis.
Please refer to the original proposal for the detail.

E. Conclusions
We have established a whole panel of wild-type and mutant erbB2 gene transfectants, which can be used to further understanding of antiapoptotic signaling of erbB2 gene.

F. Publication
Appendices

Fig.1 Western Blotting shows wild-type and mutant erbB2 proteins expression

![Western Blot Image](image1)

Fig.2 Western Blotting shows ErbB2 mutant transfectants erbB2 protein tyrosine phosphorylation levels

![Western Blot Image](image2)
Overexpression of ErbB2 Blocks Taxol-Induced Apoptosis by Upregulation of p21<sup>CIP1</sup>, which Inhibits p34<sup>Cdc2</sup> Kinase

Dihua Yu,*† Tong Jing,* Bolin Liu,* Jun Yao,* Ming Tan,* Timothy J. McDonnell,† and Mien-Chie Hung‡
*Department of Surgical Oncology
†Department of Molecular Pathology
‡Department of Tumor Biology
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas 77030

Summary

Overexpression of the receptor tyrosine kinase p185<sup>neu</sup> confers Taxol resistance in breast cancers. Here, we investigated the underlying mechanisms and found that overexpression of p185<sup>neu</sup> inhibits Taxol-induced apoptosis. Taxol activates p34<sup>Cdc2</sup> kinase in MDA-MB-435 breast cancer cells, leading to cell cycle arrest at the G2/M phase and, subsequently, apoptosis. A chemical inhibitor of p34<sup>Cdc2</sup> and a dominant-negative mutant of p34<sup>Cdc2</sup> blocked Taxol-induced apoptosis in these cells. Overexpression of p185<sup>neu</sup> in MDA-MB-435 cells by transfection transcriptionally upregulates p21<sup>CIP1</sup>, which associates with p34<sup>Cdc2</sup>, inhibits Taxol-mediated p34<sup>Cdc2</sup> activation, delays cell entrance to G2/M phase, and thereby inhibits Taxol-induced apoptosis. In p21<sup>CIP1</sup>-antisense-transfected MDA-MB-435 cells or in p21<sup>CIP1</sup>−/− MEF cells, p185<sup>neu</sup> was unable to inhibit Taxol-induced apoptosis. Therefore, p21<sup>CIP1</sup> participates in the regulation of a G2/M checkpoint that contributes to resistance to Taxol-induced apoptosis in p185<sup>neu</sup>-overexpressing breast cancer cells.

Introduction

The ErbB2 (or HER-2, neu) gene encodes a 185 kDa transmembrane glycoprotein (p185), and it was found to be amplified, overexpressed, or both in approximately 30% of human breast carcinomas (Slamon et al., 1987). Individuals with such carcinomas had a significantly lower overall survival rate and a shorter time to relapse than did patients whose tumors did not overexpress ErbB2. We previously demonstrated that ErbB2 overexpression can confer breast cancer cells increased resistance to paclitaxel (Taxol) (Yu et al., 1996). Our experimental findings are supported by recent reports from a phase III clinical trial that the response rate to Taxol was significantly improved in breast cancer patients when ErbB2 was downregulated using Herceptin antibodies that bind to the extracellular domain of ErbB2 (Dickman, 1998). However, the molecular mechanisms underlying ErbB2-mediated Taxol resistance in breast cancers were not defined.

Taxol is a potent and highly effective antineoplastic agent for the treatment of advanced, drug-refractory, metastatic breast cancers (Holmes et al., 1991). At the cellular level, Taxol induces tubulin polymerization and microtubule formation (Horwitz, 1992), blocks the cell cycle in mitosis, and induces programmed cell death (apoptosis) (Wahl et al., 1996). At the biochemical level, Taxol has been shown to increase the release of tumor necrosis factor (TNF) (Ding et al., 1990), to increase lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation (Manthey et al., 1992), and to activate p34<sup>Cdc2</sup> inappropriately (Donaldson et al., 1994). However, the molecular pathway of Taxol-mediated cytotoxicity and apoptosis remains to be elucidated.

Apoptosis is a predominant mechanism by which cancer chemotherapeutic agents (including Taxol) kill cells (Fisher, 1994). The failure of cancer cells to detect drug-induced damage and to activate apoptosis may lead to multidrug resistance. Many intracellular signaling pathways involving growth factor receptors and their downstream signaling molecules may converge in a common apoptosis-regulatory mechanism (Collins and Rivas, 1993). Although it is known that overexpression of ErbB2 receptor confers resistance to Taxol (Yu et al., 1996), the potential impact of ErbB2 overexpression on Taxol-induced apoptosis has not been previously explored.

p34<sup>Cdc2</sup>-cyclin B complexes are known to catalyze chromosomal condensation and nuclear envelope breakdown during mitosis. Growing evidence indicates that p34<sup>Cdc2</sup>-cyclin B may play a role in the nuclear changes accompanying apoptosis. Activation of the p34<sup>Cdc2</sup> kinase at the G2/M transition is precisely controlled by multiple regulatory factors including cyclin B, Cdc25C, Myt1, Wee1, and others (for review, see Coleman and Dunphy, 1994). Interestingly, when Cdk2 kinase activity in extracts of Xenopus eggs was inhibited by p21<sup>CIP1</sup>, mitosis was blocked and inactive p34<sup>Cdc2</sup>-cyclin B accumulated (Guadagno and Newport, 1996). Whether p21<sup>CIP1</sup> may directly inhibit p34<sup>Cdc2</sup> requires further investigation.

p21<sup>CIP1</sup> (p21<sup>MMI</sup>, p21<sup>IP</sup>) encodes a 21 kDa protein and was discovered as a Cdk inhibitor (Harper et al., 1993) as well as a wild-type Cdk5-inhibitable gene (El-Deiry et al., 1993). Later, p21<sup>CIP1</sup> was considered critical for the coordination of the S and M phases of the cell cycle, because doxorubicin-treated p21<sup>−/−</sup> cancer cells but not parental p21<sup>+/−</sup> cells experienced multiple rounds of S phase without mitosis and then became apoptotic (Waldman et al., 1996). Although p21<sup>CIP1</sup> has recently been shown to contribute to regulation of the G2/M transition (Dulic et al., 1998), the biological impact of such regulation when cells suffer DNA damage or disorder in mitosis (e.g., exposure to Taxol) has not been clearly demonstrated.

In an attempt to understand the molecular mechanisms underlying ErbB2-mediated Taxol resistance, we conducted the current study and found that ErbB2 blocks Taxol-induced apoptosis in breast cancer cells by upregulation of p21<sup>CIP1</sup>, which participates in the negative regulation of Taxol-mediated p34<sup>Cdc2</sup> activation required for Taxol-induced apoptosis. We provide experimental evidence for the role of p21<sup>CIP1</sup> in the regulation of G2/M checkpoint and the impact of such regulation on Taxol-mediated apoptosis in breast cancer cells.

§To whom correspondence should be addressed.
study has revealed a plausible molecular mechanism underlying the Taxol resistance phenomenon in breast cancers and potentially other cancer types that overexpress ErbB2.

Results

Breast Cancer Cells Overexpressing p185
\textsuperscript{Neu} Are More Resistant to Taxol-Induced Apoptosis

The MDA-MB-435 human breast cancer cell line contains only one copy of the ErbB2 gene per haploid, expresses low levels of p185
\textsuperscript{Neu} protein, and is highly sensitive to Taxol cytotoxicity (Yu et al., 1996). To investigate whether Taxol elicited cytotoxicity by induction of apoptosis, untreated and Taxol-treated MDA-MB-435 cells were examined for apoptotic morphology using light microscopy and transmission electron microscopy (TEM). Dramatic morphological changes specific to apoptotic cells (e.g., chromatin condensation, formation of membrane-bound apoptotic bodies, etc.) were observed in Taxol-treated cells but not in the untreated cells (Figure 1A). We also detected DNA fragmentation in Taxol-treated MDA-MB-435 cells (Figure 1C). Thus, induction of apoptosis is an important mechanism underlying the cytotoxic effects of Taxol on these breast cancer cells.

To study whether p185
\textsuperscript{Neu} overexpression may confer Taxol resistance by blocking Taxol-induced apoptosis, we used a panel of cell lines with the same genetic background but expressing different levels of p185
\textsuperscript{Neu} (Figure 1B). The 435.eB transfectants (eB1, eB2, eB3, and eB4) were generated by transfecting MDA-MB-435 cells with the pCMVerbB2 plasmid containing the full-length normal human ErbB2 cDNA, and they express p185
\textsuperscript{Neu} at 258-, 149-, 135-, and 165-fold, respectively, that of the parental MDA-MB-435 cells (Yu et al., 1996). The p185
\textsuperscript{Neu} levels in these 435.eB transfectants are comparable to, or lower than, that of the SKBR3 breast cancer cells established from a different primary breast tumor, which express p185
\textsuperscript{Neu} at 262-fold of that of the MDA-MB-435 cells (Yu et al., 1996). The control 435.neo.1 and 435.neo.pool cell lines were established by transfecting the neomycin resistance gene pSV2-neo alone into MDA-MB-435 cells, and they express p185
\textsuperscript{Neu} at levels similar to that of the MDA-MB-435 cells (Yu et al., 1996). The eB1.eB1Ra and eB2Ra are two spontaneous revertants derived from the 435.eB1 and 435.eB2 that lost the transfected ErbB2 gene and do not overexpress p185
\textsuperscript{Neu} anymore. These cell lines that express different levels of p185
\textsuperscript{Neu} were assayed for susceptibility to Taxol-induced apoptosis by DNA fragmentation assays (Figure 1C). Taxol-treated MDA-MB-435, 435.neo, and 435.neo.pool cells (0.02 μM) formed DNA ladders, whereas DNA ladder formation was inhibited in all four of the 435.eB transfectants. DNA ladders in 435.eB transfectants appeared only when a 10-fold higher concentration of Taxol was added. The eB1.eB1Ra and eB2Ra revertants demonstrated DNA ladders similar to that of the parental MDA-MB-435 cells, that is, these revertants have lost the apoptosis-resistant phenotype of the 435.eB1 and 435.eB2 cells due to the loss of p185 expression. The results indicate that overexpression of p185
\textsuperscript{Neu} in breast cancer cells can inhibit Taxol-induced apoptosis.

Taxol Induces Apoptosis at the G2/M Phase of the Cell Cycle, which Is Impeded by Overexpression of p185
\textsuperscript{Neu}

Taxol was previously shown to induce phosphorylation of Bcl-2, thereby inactivating Bcl-2 and inducing apoptosis in several cancer types (Blagosklonny et al., 1996). Phosphorylated Bcl-2 proteins can be detected as slower migrating bands in Western blots. No significant difference in Bcl-2 protein levels or Bcl-2 phosphorylation was observed between Taxol-treated, apoptosis-sensitive MDA-MB-435 cells and apoptosis-resistant 435.eB transfectants by Western blot analysis using Bcl-2 antibody (Figure 2A). Therefore, inhibition of Taxol-induced apoptosis by p185
\textsuperscript{Neu} was unlikely to be the result of increased Bcl-2 activity.

It has been recognized that the position of cells in the cell cycle may play a role in determining susceptibility to apoptosis in many cell types (Meikrantz and Schlegel, 1996). To explore the mechanisms of Taxol-induced
apoptosis and p185^bos-mediated antiapoptosis, we examined the cell cycle stage or stages where Taxol induced apoptosis by multiparameter flow cytometry. Cell cycle stage and apoptosis were simultaneously determined by measuring DNA content and by labeling DNA strand breaks with biotinylated dUTP (Darzynkiewicz et al., 1992). Flow cytometric analysis demonstrated that the majority of the untreated 435.neo control cells were at the G1 phase of the cell cycle without significant DNA strand breaks (Figure 2Ba). After 15 hr of 0.02 µM Taxol treatment, 72% of these p185^-low-expressing cells progressed to the G2/M phase (Figure 2Bb). After 21 hr of Taxol treatment, more of these cells were arrested at the G2/M phase, and some of these cells were at the sub-G1 phase indicative of apoptosis (Figure 2Bc). That the 435.neo cells were arrested at G2/M by Taxol seems to be an abortive event, since 21% of cells died at the G2/M phase as demonstrated by a high-level dUTP labeling indicating apoptotic DNA strand breaks (Figure 2Bc, over the sloped line). In contrast, the Taxol-resistant 435.eB1 cells progressed less effectively toward the G2/M phase after 15 hr of Taxol treatment (55%, Figure 2Be) and demonstrated minimal apoptotic DNA strand breaks (5%) after 21 hr of Taxol treatment (Figure 2Bf), despite untreated 435.eB cells showing a similar cell cycle distribution profile to that of the untreated 435.neo cells (Figure 2Bd). These results indicate that Taxol-induced apoptosis of the 435.neo cells occurs preferentially at the G2/M phase of the cell cycle, whereas overexpression of p185^bos in 435.eB cells delays Taxol-mediated cell entrance to the G2/M phase, thereby inhibiting Taxol-induced apoptosis.

Taxol Induces G2/M Arrest and Apoptosis by Activation of p34^cyc-Cyclin B Kinase
Entry to mitosis is delicately controlled by the Cdk-cyclin complex consisting of the p34^cyc protein kinase and cyclin B (Draetta et al., 1989). Here, we show that Taxol can activate the p34^cyc-cyclin B1 kinase in MDA-MB-435 breast cancer cells (Figures 3A and 3C, lane 1 versus lane 4), which correlated with the induction of apoptosis at the G2/M phase (Figure 3Db). To determine whether the activation of p34^cyc-cyclin B1 kinase was required for Taxol-induced apoptosis, we investigated the effects of inhibiting p34^cyc kinase on Taxol-induced apoptosis by two approaches. First, we examined the effects of olomoucine, a potent chemical inhibitor of p34^cyc, on Taxol-induced apoptosis. MDA-MB-435 cells were cultured for 24 hr in Taxol-free media or Taxol-containing media with the addition of olomoucine (a control chemical) or olomoucine, respectively. The differently treated cells were then assayed for the p34^cyc kinase activities and apoptotic cell death. Olomoucine, but not isoolomoucine, reduced (30%) Taxol-mediated activation of p34^cyc (Figure 3A). Parallel to the inhibition of p34^cyc kinase activity, olomoucine effectively inhibited Taxol-induced apoptosis, since flow cytometry demonstrated that MDA-MB-435 cells treated with olomoucine plus Taxol had dramatically reduced sub-G1 apoptotic cells compared with cells treated with Taxol alone or with isoolomoucine plus Taxol (Figure 3B).

Since olomoucine functions by competing for the ATP binding domain of the kinase and may have weak inhibitory effects on other Cdns (Vesely et al., 1994), our second approach was to specifically inhibit p34^cyc using the dominant-negative mutant of p34^cyc, pCMVcdc2-dn (van den Heuvel and Harlow, 1993). MDA-MB-435 cells were transfected with the pCMVcdc2-dn, or pCMVneo for 36 hr, then cultured with or without Taxol for an additional 21 hr and harvested. RNA expression from the transfected Cdc2-dn was detected by RT-PCR using PCR primers that specifically amplify Cdc2-dn (Figure 3G). Taxol-mediated activation of p34^cyc was reduced in the pCMVcdc2-dn-transfected cells (76% reduction), whereas no discernible inhibitory effect was observed in the pCMVneo-transfected cells (Figure 3C). Meanwhile, Cdc2-dn retarded Taxol-induced cell progression to
Figure 3. Activation of p34<sup>cdc2</sup> Kinase Is Required for Taxol-Mediated Apoptosis

(A) Inhibition of p34<sup>cdc2</sup> kinase activity by olomoucine. MDA-MB-435 cells were cultured for 24 hr in Taxol-free media, or Taxol-containing media (0.02 μM), alone, with addition of isoolomoucine, or with olomoucine. These differently treated cells were then assayed for p34<sup>cdc2</sup> kinase activities by determining their ability to phosphorylate histone H1 substrate.

(B) Olomoucine inhibited Taxol-induced apoptosis. MDA-MB-435 cells treated in a similar manner as in Figure 3A were collected and stained with propidium iodide for flow cytometric analysis. Apoptosis was represented by the appearance of cells at the sub-G1 phase.

(C) Inhibition of p34<sup>cdc2</sup> kinase activity by the dominant-negative mutant of p34<sup>cdc2</sup> (Cdc2-dn). MDA-MB-435 cells were mock transfected or transfected with pCMVneo vector, or with pCMVcdc2-dn using cationic liposome, DC-Chol:DOPE. Thirty-six hours later, cells were grown in fresh media with (0.02 μM) or without Taxol for another 21 hr. These differently treated cells were then harvested and assayed for p34<sup>cdc2</sup> kinase activities as in (A). The p34<sup>cdc2</sup> protein levels were determined by Western blot analysis using anti-Cdc2 antibodies (bottom). Activation of p34<sup>cdc2</sup> kinase activities was reduced (76.2% reduction after normalized with Cdc2 protein level) in the Cdc2-dn-transfected cells compared to that in mock-transfected cells.

(D) Inhibition of Taxol-induced apoptosis by Cdc2-dn. Cells treated in a similar manner as in (C) were collected and detected for Taxol-induced apoptosis by double-label flow cytometry analysis (a-d) and by DNA fragmentation assay (e, lanes 1-6 correspond to lanes 1-6 in [C]).

(E) Inhibition of Cdc2 kinase activity by the dominant-negative mutant of Cdc2 (Cdc2-dn). MDA-MB-435 cells were treated and assayed in a similar manner as in (C) except pCMVcdc2-dn was used here.

(F) Cdc2-dn did not inhibit Taxol-induced apoptosis. MDA-MB-435 cells were treated and assayed in a similar manner as described in (D) except pCMVcdc2-dn was used here.

(G) RNA expression of the transfected pCMVcdc2-dn and pCMVcdc2-dn. MDA-MB-435 cells were mock transfected, transfected with pCMVcdc2-dn or pCMVcdc2-dn for 36 hr, and processed for RT-PCR experiments. RT-, PCR without reverse transcription; RT+, reverse transcription followed by PCR; control, direct PCR using pCMVcdc2-dn and pCMVcdc2-dn plasmids as PCR template, which yielded signals ~600 bp larger than that from RNA transcripts. This was due to the β-globin intron 2 sequence existing in both plasmids.
G2/M phase and dramatically reduced apoptosis compared with pCMVneo-transfected cells that were effectively blocked at the G2/M phase by Taxol and underwent apoptosis (Figure 3Dd versus 3Db). Inhibition of Taxol-induced apoptosis by Cdc2-dn in MDA-MB-435 cells was also observed using DNA fragmentation assays (Figure 3De, lane 5 versus 4). Blocking of Taxol-induced apoptosis by inhibition of p34<sup>Cdc2</sup> with olomoucine and Cdc2-dn indicated that activation of p34<sup>Cdc2</sup> was required for Taxol-induced apoptosis.

Cdk2 was previously shown to be required for entry into mitosis as a positive regulator of p34<sup>Cdc2</sup> kinase in extracts of cycling Xenopus eggs (Guadagno and Newport, 1996). We next investigated whether Cdk2 is required for Taxol-mediated entrance of MDA-MB-435 cells to G2/M phase and apoptosis using the dominant-negative mutant of Cdk2, pCMVcdk2-dn (van den Heuvel and Harlow, 1993). MDA-MB-435 cells were transfected with the pCMVcdk2-dn, or CMV vector for 36 hr, then cultured in the presence or absence of Taxol for an additional 21 hr and harvested. RNA expression from the transfected Cdk2-dn was also detected by RT-PCR (Figure 3G). Interestingly, Taxol did not activate Cdk2 kinase activity in MDA-MB-435 cells (Figure 3E, lane 1 versus lane 4), suggesting that Taxol did not induce apoptosis by activating Cdk2. Additionally, Cdk2-dn did not block Taxol-induced apoptosis in these cells (Figure 3Ff), although Cdk2-dn effectively inhibited the kinase activities of Cdk2 (Figure 3E), indicating that Cdk2 is not required for Taxol-induced apoptosis. Similarly, Cdk4 was found not necessary for Taxol-induced apoptosis in MDA-MB-435 cells (data not shown) using dominant-negative Cdk4 mutant pCMVcdk4-dn (van den Heuvel and Harlow, 1993). Taken together, activated p34<sup>Cdc2</sup>, but not Cdk2 or Cdk4, is one of the mediators for Taxol-induced apoptosis.

**Taxol-Induced Activation of p34<sup>Cdc2</sup> Is Inhibited in 435.eB Cells**

To examine whether overexpression of p185<sup>Src</sup> may inhibit Taxol-mediated activation of p34<sup>Cdc2</sup> and thereby confer resistance to Taxol-induced apoptosis, we compared the extent and kinetics of Taxol-induced activation of p34<sup>Cdc2</sup> kinase between the p185<sup>Src</sup>-low-expressing 435.neo cells and the p185<sup>Src</sup>-overexpressing 435.eB transfectants. Activation of p34<sup>Cdc2</sup> kinase in 435.neo cells was detected 2 hr after addition of Taxol, and it continued to increase 8 hr after Taxol treatment compared to that in the untreated controls (Figure 4A). However, activation of p34<sup>Cdc2</sup> kinase in the Taxol-resistant 435.eB cells is reduced to only 47% of that in the 435.neo cells (Figure 4A), whereas the p34<sup>Cdc2</sup> protein levels are similar between the 435.neo cells and 435.eB cells (Figure 4A, bottom). To investigate whether the inhibition of p34<sup>Cdc2</sup> activation by p185<sup>Src</sup> may contribute to resistance to Taxol-induced apoptosis, 435.neo cells and 435.eB cells were compared for the kinetics of Taxol-induced apoptosis using DNA fragmentation assays (Figure 4B). DNA ladders appeared in the 435.neo cells 12 hr after 0.02 \mu M Taxol treatment and became pronounced 15 hr after Taxol treatment. However, DNA ladders in the 435.eB cells did not appear until 18 hr after Taxol treatment, and the degree of DNA fragmentation was less pronounced than that in 435.neo cells. The delayed and reduced apoptotic response in the Taxol-treated 435.eB cells correlated with their lower p34<sup>Cdc2</sup> kinase activity, suggesting that inhibition of Taxol-mediated p34<sup>Cdc2</sup> activation in 435.eB cells may contribute to their resistance to Taxol-induced apoptosis.

**Elevated p21<sup>Cip1</sup> Expression in 435.eB Transfectants**

It is known that activation of p34<sup>Cdc2</sup> is precisely regulated by the accumulation of cyclin B and by three phosphorylation sites on the p34<sup>Cdc2</sup> subunit that are modulated by Cdc25 and Wee1. To determine how p185<sup>Src</sup> inhibited the activation of p34<sup>Cdc2</sup>, we compared the expression levels of these p34<sup>Cdc2</sup> regulators in the p185<sup>low-expressing</sup> 435.neo cells and p185<sup>overexpressing</sup> 435.eB cells by immunoblot analysis, and no significant difference was detected among these cells (data not shown). This suggests that overexpression of p185<sup>Src</sup> did not inhibit activation of p34<sup>Cdc2</sup> by regulating cyclin B, Cdc25, and Wee1 expression.

In addition to these regulators of p34<sup>Cdc2</sup>, p21<sup>Cip1</sup> was suggested to regulate a G2/M checkpoint, blocking the entrance of cells into M phase (Jacks and Weinberg, 1994).
To investigate whether p185*E82* may inhibit p34*cdk* kinase activity by upregulation of p21*cip*, we examined the p21*cip* expression levels in MDA-MB-435 cells and 435.neo cells that express low levels of p185*E82* and in 435.eB1 transfectants that express high levels of p185*E82*. Higher levels of p21*cip* protein were detected in the 435.eB1 transfectants compared with MDA-MB-435 and 435.neo control cells (Figure 5A), which was due to upregulation of p21*cip* mRNA expression (Figure 5B). To further investigate whether p185*E82* upregulated p21*cip* by transcriptional activation, we cotransfected into MDA-MB-435 cells the pWWP-Luc plasmid, containing 2.4 kb wild-type p21*cip* promoter and upstream sequences fused with the luciferase reporter gene (El-Deiry et al., 1993), with either the pCMVneo control vector or with increasing amounts of the pCMVerbB2, an ErbB2 expression vector (Yu et al., 1996). Luciferase activities driven by the p21*cip* promoter increased in the presence of ErbB2 expression vector in an ErbB2 concentration-dependent manner (Figure 5C). These data demonstrated that p185*E82* can upregulate p21*cip* in 435.eB1 transfectants at the transcriptional level.

p21*cip* Associates with p34*cdk* and Inhibits p34*cdk* Kinase Activity

Although p185*E82* upregulated p21*cip* expression in 435.eB1 cells and p21*cip* was shown to regulate the G2/M transition (Dulic et al., 1998; Niculescu et al., 1998), it is not clear whether the upregulated p21*cip* in 435.eB1 cells may inhibit p34*cdk* and mediate the antiproliferative function of p185*E82*. We therefore examined whether the upregulated p21*cip* in 435.eB1 cells may associate with p34*cdk* in vivo. The 435.neo and 435.eB1 cell lysates were immunoprecipitated using p21*cip* antibodies or control IgG. Immunoprecipitates (IP) and supernatants (Sup) were separated on SDS-PAGE and immunoblotted with antibodies against p34*cdk* and p21*cip*. Abundant p34*cdk* protein was detected in the 435.eB1 cell lysates of p21*cip* antibodies (Figure 5D, left panel), whereas less p34*cdk* protein remained in the supernatant due to depletion of p21*cip* (Figure 5D, middle panel). In addition, a stronger p34*cdk* signal can be detected in the 435.eB1 cells expressing high levels of p21*cip* compared with the 435.neo cells expressing low levels of p21*cip* (Figure 5D, left panel). Reverse experiments detected p21*cip* in the p34*cdk* antibody immunoprecipitates (Figure 5D, right panel). These results indicate that the upregulated p21*cip* protein in 435.eB1 cells physically associates with p34*cdk*, suggesting that upregulation of p21*cip* may contribute to inactivation of p34*cdk* kinase in 435.eB1 cells.

To examine whether p21*cip* can indeed inhibit p34*cdk*, we tested the inhibitory effects of purified recombinant GST-p21*cip* fusion protein (El-Deiry et al., 1993) on p34*cdk*-cyclin B1 kinase activity. p34*cdk*-cyclin B1 complexes were immunoprecipitated by anti-cyclin B1 antibodies, and Cdk2-cyclin B1 complexes were immunoprecipitated by anti-Cdk2 antibodies (as a positive control) from MDA-MB-435 total cell lysates. The immunoprecipitates were incubated with GST-p21*cip* or control GST protein and then assayed for kinase activity. GST-p21*cip* effectively inhibited the G2/M phase p34*cdk*-cyclin B1 kinase activity (Figure 5E, left panel). Since GST-p21*cip* could inhibit activities of p34*cdk*-cyclin B1 complexes precipitated by anti-cyclin B1 antibodies, the data indicated that p21*cip* inhibited the p34*cdk* kinases that were active in the mitosis-promoting p34*cdk*-cyclin B1 heterodimer. In the control experiment, GST-p21*cip* inhibited Cdk2 activity as expected (Figure 5E, right panel). Furthermore, the purified GST-p21*cip* fusion protein also
inhibited the activities of the purified recombinant p34Cd catcyclin B1 kinases (Figure 5E, middle panel). Therefore, p21Cip1 can directly inhibit p34Cd catcyclin B1 kinase activity in vitro.

Sensitization of 435.eB Cells to Taxol-Induced Activation of p34Cd cat and Apoptosis by Antisense p21Cip1

To investigate whether the upregulated p21Cip1 in p185Neu-overexpressing 435.eB cells may inhibit Taxol-mediated activation of p34Cd cat kinase, thereby blocking Taxol-induced apoptosis in these cells, we blocked p21Cip1 mRNA expression in 435.eB cells by transient transfection of p21Cip1 antisense oligonucleotides (P21AS) that hybridize to the transcription initiation site. In the control experiment, the 435.eB cells were transfected with scrambled p21Cip1 antisense oligonucleotide (P21S). Thirty-six hours after transfection, the 435.eB cells were treated with or without Taxol for an additional 21 hr and cell lysates harvested. Western blot analysis using p21Cip1 antibodies demonstrated that the p21Cip1 scrambled oligonucleotide-treated 435.eB cells expressed readily detectable p21Cip1 protein, and the p21Cip1 protein was slightly upregulated by Taxol (Figure 6A), which is consistent with previous reports that Taxol can induce p21Cip1 in certain cell types (Barboule et al., 1997). However, p21Cip1 antisense-treated 435.eB cells had significantly reduced p21Cip1 protein levels, and Taxol did not upregulate p21Cip1 in these cells. Higher p34Cd cat kinase activity was detected in Taxol-treated 435.eB cells transfected with p21Cip1 antisense compared with those transfected with the scrambled oligonucleotides (Figure 6B), whereas the p34Cd cat protein levels remained similar. These experiments suggest that p21Cip1 contributes to inhibition of Taxol-induced p34Cd cat activation in 435.eB cells. We next compared the induction of apoptosis by Taxol in the antisense or scrambled oligonucleotide-transfected 435.eB cells using flow cytometry (Figure 6C). The majority of the untreated 435.eB cells with scrambled oligonucleotide were at the G1 phase of the cell cycle without significant apoptotic DNA strand breaks (Figure 6C, top panel, 0 hr). After Taxol treatment for 15 hr and 21 hr, these cells cyclized toward the G2M phase of the cell cycle with no significant DNA strand breaks (Figure 6C). Although the untreated 435.eB cells with antisense p21Cip1 had similar cell cycle profiles (Figure 6C, bottom panel, 0 hr) as the control cells, these cells showed a high level of apoptotic DNA strand breaks after 15 hr of Taxol treatment that became more pronounced after 21 hr of Taxol treatment (Figure 6C). Since blocking p21Cip1 by antisense in 435.eB cells relieved the inhibition of Taxol-mediated p34Cd cat activation and sensitized the 435.eB cells to Taxol-induced apoptosis, the data indicate that upregulated p21Cip1 in 435.eB transfecants participated in the inhibition of Taxol-mediated p34Cd cat activation, which contributes to resistance to Taxol-induced apoptosis.

Overexpression of ErbB2 Does Not Inhibit Taxol-Induced Apoptosis in p21Cip1 Mouse Embryonic Fibroblasts

To further test the requirement of p21Cip1 for p185Neu antiapoptotic function, we examined whether p185Neu could block Taxol-induced apoptosis in p21Cip1 null cells. The ErbB2 expression vector (pCMVerbB2) or control vector (pCMVneo) was transfected into mouse embryonic fibroblasts (MEF) from a p21Cip1 knockout mouse (p21Cip1−/− MEF) or from a wild-type mouse (wt MEF) (Montes de Oca Luna et al., 1997). Western blot analysis using p185Neu antibodies demonstrated overexpression of p185Neu in pCMV erbB2-transfected p21Cip1−/− MEF and wt MEF compared to controls (Figure 7A). In addition, the overexpressed p185Neu in wt MEF has led to a dramatic increase of p21Cip1 expression (Figure 7A). However, although overexpression of p185Neu in wt MEF conferred resistance to Taxol-induced apoptosis, overexpression of p185Neu in p21Cip1−/− MEF did not demonstrate a similar antiapoptotic response (Figure 7B). Similar results were
G2/M phase of the cell cycle through activation of p34<sup>Cdc2</sup>. Activation of p34<sup>Cdc2</sup>-cyclin B1 kinase is required for Taxol-induced apoptosis in breast cancer cells because Taxol-mediated activation of p34<sup>Cdc2</sup> kinase occurred prior to Taxol-induced apoptosis and because inhibition of Taxol-mediated activation of p34<sup>Cdc2</sup> kinase by a chemical inhibitor and by the dominant-negative mutant of p34<sup>Cdc2</sup> diminished Taxol-induced apoptosis.

p185<sup>Erbb2</sup> Confers Resistance to Taxol-Induced Apoptosis by Inhibiting p34<sup>Cdc2</sup> Activation

Several growth factors and growth factor receptors have been shown to modulate apoptosis (Rodeck et al., 1997). Here, we have provided direct evidence that overexpression of p185<sup>Erbb2</sup> in breast cancer cells can confer resistance to Taxol-induced apoptosis. The antiapoptotic effect of p185<sup>Erbb2</sup> was also observed in p185<sup>Erbb2</sup>-overexpressing MDA-MB-361 and BT-474 breast cancer cell lines (Yu et al., unpublished data) that were established from breast tumors of other patients, indicating that resistance to Taxol-induced apoptosis in p185<sup>Erbb2</sup>-overexpressing breast cancer cells is not limited to a single cell line but is of general importance. Our data indicated that overexpression of p185<sup>Erbb2</sup> in breast cancer cells conferred resistance to Taxol-induced apoptosis via Bcl-2 independent pathways. Interestingly, overexpression of p185<sup>Erbb2</sup> in 435.eB transfectants resulted in a reduced activation of p34<sup>Cdc2</sup> kinase compared to p185-low-expressing 435.neo control cells. Moreover, inhibition of Taxol-mediated activation of p34<sup>Cdc2</sup> kinase by p185<sup>Erbb2</sup> corresponded to the delayed cell entrance to G2/M phase after Taxol treatment and paralleled the inhibition of Taxol-induced apoptosis. Therefore, at least one of the mechanisms for p185<sup>Erbb2</sup> antiapoptotic function is inhibition of Taxol-mediated activation of p34<sup>Cdc2</sup> kinase.

Upregulation of p21<sup>Cip1</sup> Contributes to Inhibition of Taxol-Mediated p34<sup>Cdc2</sup> Activation by p185<sup>Erbb2</sup>

In this study, we found that overexpression of p185<sup>Erbb2</sup> transcriptionally upregulates the Cdk inhibitor p21<sup>Cip1</sup> in MDA-MB-435 cells. The p185<sup>Erbb2</sup>-mediated upregulation of p21<sup>Cip1</sup> is p53 independent, because the MDA-MB-435 cells do not contain the wt p53 gene (Lesoon-Wood et al., 1995).

p21<sup>Cip1</sup> was originally believed not to be a universal inhibitor of Cdks but to display selectivity for G1/S phase Cdk-cyclin complexes (e.g., Cdk2) (Harper et al., 1993). Recently, p21<sup>Cip1</sup> was also demonstrated to contribute to regulation of G2/M transition (Dulic et al., 1998), and Taxol was shown to increase p21<sup>Cip1</sup> expression, which associated with p34<sup>Cdc2</sup> (Barboule et al., 1997). We report here that in 435.eB cells, p185<sup>Erbb2</sup> upregulated p21<sup>Cip1</sup>, which also complexed with p34<sup>Cdc2</sup>. Moreover, we demonstrated that p21<sup>Cip1</sup> directly inhibited the G2/M phase p34<sup>Cdc2</sup>-cyclin B1 in vitro, although less effectively than it inhibits the G1/S phase Cdk2. The association of p21<sup>Cip1</sup> with p34<sup>Cdc2</sup> in 435.eB cells and the ability of p21<sup>Cip1</sup> to inhibit p34<sup>Cdc2</sup> activity in vitro suggest that p21<sup>Cip1</sup> may inhibit p34<sup>Cdc2</sup> activity in 435.eB cells. This notion is also

Discussion

Activation of p34<sup>Cdc2</sup> Is Required for Taxol-Induced Apoptosis

Activation of p34<sup>Cdc2</sup> kinase is the biochemical step required for mitosis and has been implicated as an important event during chemotherapy-induced apoptosis in certain cancer types (Meikrantz and Schlegel, 1996). Although it was suggested that chromatin condensation and lamina disassembly during apoptosis involve different processes from those operating in mitosis, similar transient activations of p34<sup>Cdc2</sup> kinase were observed in Taxol-treated apoptotic HeLa cells (Donaldson et al., 1994). In this study, we demonstrated that Taxol induced apoptosis of MDA-MB-435 breast cancer cells at the

obtained when apoptotic cells were quantitated by staining with annexin-specific antibodies (data not shown). These findings provided consistent evidence that p21<sup>Cip1</sup> participates in the p185-mediated resistance to Taxol-induced apoptosis.

Activation of p34<sup>Cdc2</sup> kinase is the biochemical step required for mitosis and has been implicated as an important event during chemotherapy-induced apoptosis in certain cancer types (Meikrantz and Schlegel, 1996). Although it was suggested that chromatin condensation and lamina disassembly during apoptosis involve different processes from those operating in mitosis, similar transient activations of p34<sup>Cdc2</sup> kinase were observed in Taxol-treated apoptotic HeLa cells (Donaldson et al., 1994). In this study, we demonstrated that Taxol induced apoptosis of MDA-MB-435 breast cancer cells at the
supported by our data that p21<sup>53/pr</sup> antisense oligonucleotide sensitized 435.e8 cells to Taxol-mediated activation of p34<sup>cdc2</sup>. The p21<sup>53/pr</sup>-mediated dual inhibition at G1/S and G2/M phases may protect p185-overexpressing breast cancer cells from Taxol-induced apoptosis: p21<sup>53/pr</sup> directly inhibits Taxol-mediated activation of p34<sup>cdc2</sup>, which delays or prevents cell entrance to G2/M phase, resulting in inhibition of apoptosis; or p21<sup>53/pr</sup> arrests those cells progressing through aberrant mitosis in G1, which indirectly prevents or delays the cells from entering G2/M phase and undergoing apoptosis. Although multiple mechanisms may be involved, inhibition of p34<sup>cdc2</sup> by p21<sup>53/pr</sup> is likely one of the major mechanisms of apoptosis resistance in p185-overexpressing cells, since activation of p34<sup>cdc2</sup>, but not of Cdk2 or Cdk4, is required for Taxol-induced apoptosis.

**Molecular Basis of Taxol-Induced Apoptosis and p185<sup>53/pr</sup> Antiapoptosis**

Based on previous studies and data presented in this study, we propose a model for Taxol-induced apoptosis and p185<sup>53/pr</sup>-mediated antiapoptosis in breast cancer cells. Taxol can induce activation of p34<sup>cdc2</sup> kinase in MDA-MB-435 breast cancer cells that contributes to the induction of apoptosis at the G2/M phase, whereas overexpression of p185<sup>53/pr</sup> in MDA-MB-435 cells (435.e8 transfectants) impedes Taxol-induced apoptosis by upregulation of the Cdk inhibitor p21<sup>53/pr</sup>, which in turn inhibits Taxol-mediated activation of p34<sup>cdc2</sup>. This model synthesized the critical role of the G2/M Cdk p34<sup>cdc2</sup> in apoptosis induction, the function of p21<sup>53/pr</sup> as a mammalian (human breast cancer) cell G2/M Cdk inhibitor, and the effects of overexpression of the receptor tyrosine kinase p185<sup>53/pr</sup> on p21<sup>53/pr</sup> expression into our understanding of the molecular basis of Taxol-induced apoptosis and p185<sup>53/pr</sup> antiapoptosis. Furthermore, the model provides a molecular mechanism, although it may not be the only mechanism, that underlies the Taxol-resistance phenomenon in ErbB2-overexpressing breast cancers.

**Experimental Procedures**

**Cell Lines and Culture**

The human breast cancer cell line MDA-MB-435, the 435.e8 transfectants, their revertants, and control 435.neo cells were obtained, established, and cultured as previously reported (Yu et al., 1996). The p21<sup>-/-</sup> MEF and wt MEF were from Dr. Guillermina Lozano (The University of Texas, M. D. Anderson Cancer Center).

**Antibodies and Reagents**

Antibodies were purchased from commercial sources: human p34<sup>cdc2</sup>, cyclin B1 monoclonal antibodies, and Cdk2 polyclonal antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); Bcl-2 antibody from DAKO Corporation (Carpinteria, CA); human p21<sup>53/pr</sup> polyclonal and p185<sup>53/pr</sup> monoclonal antibodies from Oncogene Science, Inc. (Cambridge, MA); and β-actin monoclonal antibody from Sigma (St. Louis, MO). Taxol was purchased from Mead Johnson, Inc. (Princeton, NJ). Recombinant p34<sup>cdc2</sup>-cyclin B1 was purchased from New England BioLabs, Inc. (Beverly, MA).

**Transmission Electron Microscopy**

Cells were washed and fixed in 2% glutaraldehyde in 0.2 M sodium cacodylate buffer overnight at 4°C. Cells were postfixed in cacodylate-buffered 1% osmium tetroxide, dehydrated, and embedded in epon. Thin sections were poststained with uranyl acetate and lead citrate and viewed on a JOEL JEM 1200 Ex transmission electron microscope.

**DNA Fragmentation Assay**

Approximately 1 x 10<sup>6</sup> cells were incubated on ice in 100 μl of DNA isolation buffer (10 mM Tris, 1 mM EDTA, and 0.2% Triton X-100) for 30 min and then added with 100 μl of PBS. After centrifugation, the low molecular weight DNA was extracted from the supernatant with phenol/chloroform and precipitated with ethanol. Ten micrograms of DNA from each sample was analyzed by 1.8% agarose gel electrophoresis.

**Flow Cytometry Analysis**

Cells were harvested by trypsinization and fixed in 1% formaldehyde on ice for 20 min and washed once with PBS. For multiparameter flow cytometry analysis, the cells were incubated in terminal deoxynucleotidyl transferase (TdT) solution (0.1 M sodium cacodylate, 1 mM CoCl<sub>2</sub>, 0.1 mM dithiothreitol, 0.05 mg/ml bovine serum albumin, 10 U TdT, and 0.5 mM biotin-16-dUTP) at 37°C for 30 min, transferred to 100 μl of staining solution (4 × SSC, 5% dry milk, 0.1% Triton X-100, and 2.5 mg/ml Avidin-FITC) and incubated in the dark at room temperature for 30 min. Finally, the cells were stained in 500 μl of propidium iodide (PI) solution (0.5 μg/ml of PI and 0.1% RNase A). For single-label flow cytometry analysis, cultured cells were harvested and fixed in a similar manner and then stained in 500 μl of PI solution. Flow cytometry was performed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA). Cell cycle profile was analyzed using MultiCycle software (Phoenix Flow Systems, San Diego, CA), and FITC signal was analyzed using Epics Elite Software (Coulter Corp., Miami, FL).

**Immunocomplex-Kinase Assay**

Cells (3 x 10<sup>4</sup>) were lysed with the immunoprecipitation (IP) buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris at pH 7.4, 1 mM ethylene glycol-bis-tetraacetic acid, 0.2 mM sodium vanadate, 0.2 mM phenylmethylsulfonyl fluoride, and 0.2% NP-40). Forty micrograms of protein from each sample was incubated at 4°C for 3 hr with 1 μg of antibodies and for another 3 hr after addition of protein A-agarose. The immunoprecipitates were washed twice with IP buffer and once with kinase buffer (10 mM Tris [pH 7.4], 150 mM NaCl, 10 mM MgCl<sub>2</sub>, and 0.5 mM DTT) and resuspended in 40 μl kinase buffer containing 1 μg of histone H1, 25 μM of ATP, and 2.5 μCi of γ<sup>32</sup>PATP. Following 30 min incubation at 30°C, the reaction was terminated by adding 40 μl of 2× SDS sample buffer and analyzed by autoradiography.

**Immunoprecipitation and Immunoblotting**

Immunoprecipitation was performed as described in Immunocomplex-Kinase Assay, and immunoblot analyses were performed as described previously (Yu et al., 1990).

**Reverse Transcriptase-Polymerase Chain Reaction**

Total RNA was isolated using RNAzol reagent (Tel-Test Inc., Friendswood, TX). Reverse transcription was performed using SuperScript Preamplification System (Life Technologies, Inc., Gaithersburg, MD). Ten percent of the RT products (2 μl) were used for 30 cycles of PCR (94°C 30 s, 56°C 30 s, 72°C 45 s) using GeneAmp System 9600 (Perkin Elmer, Norwalk, CT). The sequence of forward primer for the β-globin gene is GGACGTTGACATTCGAGAATTC (both pCMVcd2c-dn and pCMVcd2c-dn contain this β-globin gene sequence at the 5' of inserts). The sequence of reverse primers are GGAGCCAGACGCCAATTCTC for Cdc2 and GAGGAGATTGGAGGCTGCTGA for Cdk2, respectively.

**Northern Blot Analysis**

Twenty micrograms of RNA was denatured with glyoxal buffer, separated by electrophoresis on a 1% agarose gel in 10 mM NaPO<sub>4</sub> (pH 6.8) buffer, and blotted onto a nylon membrane. The membrane was hybridized at 65°C with the 32P-labeled p21<sup>53/pr</sup> cDNA probe for detection of p21<sup>53/pr</sup> or with a β-actin cDNA probe as an internal loading control.
Luciferase Assays

MDA-MB-435 cells were cotransfected with pCMV-lacZ and the pWWP-Luc reporter gene with either the pCMVneo control vector or with the pCMVverb2 expression vector using cationic liposome. Forty hours later, cells were lysed with 500 µl of 1 x lysis buffer (Promega, Madison, WI) for 10 min at room temperature. After centrifugation, 100 µl of supernatant was used for a ß-gal assay to determine transfection efficiency, and 15–30 µl of supernatant was added to 100 µl of reconstituted luciferase assay reagent in the luciferase assay kit (Promega). Light emission was detected by a luminometer.

Use of GST-p21 for inhibition of Cdc2-Cyclin B1 Kinase Activity

The GST-p21 fusion protein of GST-p21 protein was isolated from BL21 (DE3) bacteria transformed with either pGEX-2T-WAF1-S or pGEX-2T as previously described (El-Deiry et al., 1993). Immuncprecipitates of anti-cyclin B1 or anti-Cdk2 from MDA-MB-435 total cell lysates or recombinal Cdc2-Cyclin B1 kinases were incubated at 30°C for 30 min in 20 µl of kinase buffer with 10 µg of GST-p21 or GST protein. Samples were then processed for kinase assay.

Antisense Oligonucleotides

Phosphorothioate oligodeoxynucleotides (5 µg) and cationic liposome, DC-Chol:DOPE (75:25 mol) were incubated at 37°C for 15 min. The oligonucleotide–liposome mixture was diluted with serum-free medium and added to the cells for 36 hr. Cells were then treated with or without 0.02 µM Taxol for various times. We used antisense oligonucleotides based on the p21WAF1 coding sequence complementary to the region of the initiation codon (p21-AS, 5'-CCGAGCAGCGGTCTGTCATGCCC-3') and the scrambled p21WAF1 antisense oligonucleotides as control (p21-S, 5'-CGCGCACGAGCGGTCTGTCATGCCC-3') which were purchased from Genosys Inc. (Woodlands, TX).

Acknowledgments

The authors thank Dr. Wafik S. El-Deiry for the GST-p21 construct; Dr. Guillermia Lozano for p21–MEF and wt MEF; Dr. Jeffrey W. Harper for pCMVcdk2-dn and pCMVcdk4-dn; Dr. William Klein, Dr. Daniel Carson, and Ms. Rebecca Grijalva for critical reading of the manuscript; Mr. Dantong Sun for technical assistance; and Ms. Karen Ramirez for flow cytometry analysis. This research was supported by Grants CA60488 from the National Institutes of Health (to D. Y.), DAMD17-98-1-3338 from the United States Army Medical Research and Materiel Command (USAMRMC) (to D. Y.), M. D. Anderson Breast Cancer Research Program (fund to D. Y.), and predoctoral fellowships from USAMRMC (T. J. and M. T.) and from R. B. Hite foundation (J. Y.).

Received March 2, 1998; revised September 25, 1998.

References

